Amanote Research
Register
Sign In
Pcn94 - Cost-Effectiveness of Cabozantinib Versus Sunitinib or Pazopanib as First-Line Treatment of Patients With Advanced Renal Cell Carcinoma in the Uk
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.176
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
E. Skentzou
J. Meng
J. Lister
L. Gray
Publisher
Elsevier BV
Related search
Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma
Oncotarget
Oncology
Cost-Effectiveness Analysis of Sunitinib Versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
International Journal of Technology Assessment in Health Care
Health Policy
Cost-Effectiveness and Cost-Utility Analysis of Sunitinib Versus Sorafenib and Bevacizumab + Interferon-Alfa as First-Line Treatment for Metastatic Renal Cell Carcinoma in Ecuador
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer
Oncology
Urology
Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
Pcn144 - Cost-Effectiveness of Cabozantinib for Patients With Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Oncologist
Cancer Research
Medicine
Oncology
Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma
Current Oncology
Oncology
